This product comprises a polyclonal population of Raji cells that have been edited using CRISPR/Cas9 to disrupt the EFEMP1 gene, generating a functional knockout of fibulin-3. The polyclonal format retains the genetic heterogeneity of the parental cell line while ablating target gene expression, enabling studies that more closely reflect the complexity of tumor cell populations. Researchers can utilize these cells to investigate EFEMP1-dependent mechanisms without confounding clonal artifacts.
The Raji cell line is a well-characterized human B-cell model derived from an EBV-positive Burkitt lymphoma. Raji cells display features of mature B lymphocytes, including the capacity for antibody production and antigen presentation, and are extensively employed in immunology, oncology, and signal transduction research. Their EBV-transformed status provides a relevant context for studying viral interactions with host gene networks.
EFEMP1 encodes fibulin-3, an extracellular matrix glycoprotein that functions predominantly as a modulator of TGF-?? and Notch signaling cascades. Fibulin-3 is transcriptionally regulated by TGF-??, HIF1A, SP1, and miR-144, and it physically interacts with TIMP3, elastin, collagen IV, and integrins to influence cell adhesion and ECM organization. Downstream of fibulin-3, the activity of matrix metalloproteinases MMP-2 and MMP-9 is altered, along with modulation of EGFR and Notch pathway components. Through these interactions, fibulin-3 integrates ECM-derived cues to regulate cell proliferation, migration, and angiogenic responses.
In the context of Raji B-lymphoma cells, disruption of EFEMP1 eliminates fibulin-3-mediated ECM signaling, potentially perturbing the crosstalk between tumor cells and their microenvironment. Given the role of fibulin-3 in suppressing proliferation and angiogenesis, its loss may enhance tumorigenic traits such as increased proliferation and altered adhesion. This knockout model therefore provides a valuable system for dissecting how ECM remodeling contributes to B-cell lymphoma progression and for identifying vulnerabilities that arise from disrupted ECM-receptor interactions.
Key applications include tumor biology studies, extracellular matrix interaction analyses, drug resistance research, and B-cell lymphoma modeling. The polyclonal knockout cells are compatible with a range of downstream assays, including western blotting, RT-qPCR, RNA-seq, flow cytometry, adhesion and migration assays, proliferation and apoptosis analyses, and xenograft tumor growth models. By employing this tool, investigators can perform functional genomics experiments and preclinical evaluations of therapeutics targeting the tumor microenvironment. For additional product details and ordering information, please contact Ascent Research.
